Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRobert J. SoifferEWEdmund K. WallerSVSumithira Vasu

Discussion

Loading...

Member takes

Overview

Observational analysis shows pre-HCT FLT3 inhibition and time to HCT influence MRD in AML, suggesting refined treatment strategies.

Key Points

  • Participants with early HCT and pre-HCT FLT3 inhibition had improved outcomes, highlighting a need for tailored therapies.
  • A significant subgroup analysis identified local practice patterns affecting MRD levels prior to transplantation.
  • Observational analysis across many countries demonstrated diverse treatment impacts, with notable regional differences in outcomes.
  • Findings point to the importance of optimizing FLT3 inhibitor use and timing to enhance MRD levels before HCT.

Cite This Study

Soiffer et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d76bhttps://doi.org/10.1182/blood-2025-1058
View Full Paper
Ask AI
Bookmark
Share